1112178-37-6

Basic information

• Product Name: N-(3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrimidine-4-carboxamide
• Synonyms: N-(3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrimidine-4-carboxamide
• CAS NO: 1112178-37-6
• Molecular Weight: 325.33
• Mol File: 1112178-37-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-(3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrimidine-4-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrimidine-4-carboxamide(1112178-37-6)
• EPA Substance Registry System: N-(3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrimidine-4-carboxamide(1112178-37-6)

Safety Data

• Hazardous Substances Data: 1112178-37-6(Hazardous Substances Data)

Upstream product

• 1780-26-3 2,4-dichloro-2-methylpyrimidine 
• 17551-52-9 2-methyl-4-hydroxy-6-chloropyrimidine 
• 64532-22-5 methyl 6-hydroxy-2-methylpyrimidine-4-carboxylate 
• 1112178-31-0 methyl-6-chloro-2-methylpyrimidine-4-carboxylate 

Downstream Products

• 1112168-79-2 N-(3-methoxy-benzyl)-6-(2-((trans-4-cyano-cyclohexyl)methyl)-2H-tetrazol-5-yl)-2-methyl-pyrimidine-4-carboxamide 
• 1112170-02-1 N-(3-methoxy-benzyl)-6-[2-(5,5-bis(hydroxymethyl)-[1,4]dioxan-2-ylmethyl)-2H-tetrazol-5-yl]-2-methyl-pyrimidine-4-carboxamide 
• 1112169-60-4 N-(3-methoxy-benzyl)-6-(2-(((2R,5S)-5-hydroxymethyl-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methyl-pyrimidine-4-carboxamide 
• 1112169-58-0 N-(3-methoxy-benzyl)-6-(2-(((2S,5R)-5-hydroxymethyl-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methyl-pyrimidine-4-carboxamide 
• 1112185-20-2 rac-N-(3-methoxy-benzyl)-6-(2-(((2S*,5R*)-5-hydroxymethyl-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methyl-pyrimidine-4-carboxamide 
• 1112168-75-8 methyl trans-4-((5-(6-((3-methoxybenzyl)carbamoyl)-2-methyl-pyrimidin-4-yl)-2H-tetrazol-2-yl)methyl)cyclohexanecarboxylate 
• 1112169-48-8 6-(2-(((S)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-N-(3-methoxybenzyl)-2-methyl-pyrimidine-4-carboxamide 
• 1112169-39-7 6-(2-(((R)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-N-(3-methoxybenzyl)-2-methyl-pyrimidine-4-carboxamide 
• 1112169-35-3 rac-6-(2-((1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-N-(3-methoxybenzyl)-2-methyl-pyrimidine-4-carboxamide 
• 1112178-92-3 tert-butyl (S)-2-((5-(6-((3-methoxybenzyl)carbamoyl)-2-methylpyrimidin-4-yl)-2H-tetrazol-2-yl)methyl)morpholine-4-carboxylate 
• 1112178-96-7 tert-butyl (R)-2-((5-(6-((3-methoxybenzyl)carbamoyl)-2-methylpyrimidin-4-yl)-2H-tetrazol-2-yl)methyl)morpholine-4-carboxylate 

Relevant articles and documents

Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis

Matrix metalloproteinase-13 (MMP-13) is a zinc-dependent protease responsible for the cleavage of type II collagen, the major structural protein of articular cartilage. Degradation of this cartilage matrix leads to the development of osteoarthritis. We previously have described highly potent and selective carboxylic acid containing MMP-13 inhibitors; however, nephrotoxicity in preclinical toxicology species precluded development. The accumulation of compound in the kidneys mediated by human organic anion transporter 3 (hOAT3) was hypothesized as a contributing factor for the finding. Herein we report our efforts to optimize the MMP-13 potency and pharmacokinetic properties of non-carboxylic acid leads resulting in the identification of compound 43a lacking the previously observed preclinical toxicology at comparable exposures.